Halozyme Therapeutics Number Of Shares Shorted vs. EBITDA
| HALO Stock | USD 42.57 3.08 6.75% |
| Current Value | Last Year | Change From Last Year | 10 Year Trend | ||||||
|---|---|---|---|---|---|---|---|---|---|
| Gross Profit Margin | 0.61 | 0.768 |
|
|
For Halozyme Therapeutics profitability analysis, we use financial ratios and fundamental drivers that measure the ability of Halozyme Therapeutics to generate income relative to revenue, assets, operating costs, and current equity. These fundamental indicators attest to how well Halozyme Therapeutics utilizes its assets to generate profit and value for its shareholders. The profitability module also shows relationships between Halozyme Therapeutics's most relevant fundamental drivers. It provides multiple suggestions of what could affect the performance of Halozyme Therapeutics over time as well as its relative position and ranking within its peers.
Halozyme |
Halozyme Therapeutics' Revenue Breakdown by Earning Segment
Check out Risk vs Return Analysis.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Halozyme Therapeutics. If investors know Halozyme will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Halozyme Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth 0.721 | Earnings Share 2.82 | Revenue Per Share 7.431 | Quarterly Revenue Growth 0.343 | Return On Assets 0.1487 |
The market value of Halozyme Therapeutics is measured differently than its book value, which is the value of Halozyme that is recorded on the company's balance sheet. Investors also form their own opinion of Halozyme Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Halozyme Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Halozyme Therapeutics' market value can be influenced by many factors that don't directly affect Halozyme Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Halozyme Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Halozyme Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Halozyme Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.
Halozyme Therapeutics EBITDA vs. Number Of Shares Shorted Fundamental Analysis
Comparative valuation techniques use various fundamental indicators to help in determining Halozyme Therapeutics's current stock value. Our valuation model uses many indicators to compare Halozyme Therapeutics value to that of its competitors to determine the firm's financial worth. Halozyme Therapeutics is rated # 4 in number of shares shorted category among its peers. It is one of the top stocks in ebitda category among its peers totaling about 44.10 of EBITDA per Number Of Shares Shorted. At this time, Halozyme Therapeutics' EBITDA is very stable compared to the past year. The reason why the comparable model can be used in almost all circumstances is due to the vast number of multiples that can be utilized, such as the price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S), price-to-cash flow (P/CF), and many others. The P/E ratio is the most commonly used of these ratios because it focuses on the Halozyme Therapeutics' earnings, one of the primary drivers of an investment's value.Halozyme EBITDA vs. Number Of Shares Shorted
Number of Shares Shorted is the total amount of shares that are currently sold short by investors. When a stock is sold short, the short seller assumes the responsibility of repurchasing the stock at a lower price. The speculator will make money if the stock goes down in price or will experience a loss if the stock price goes up.
Halozyme Therapeutics |
| = | 10.25 M |
If a large number of investors decide to short sell an equity instrument within a small period of time, their combined action can significantly affect the price of the stock.
EBITDA stands for earnings before interest, taxes, depreciation, and amortization. It is a measure of a company operating cash flow based on data from the company income statement and is a very good way to compare companies within industries or across different sectors. However, unlike Operating Cash Flow, EBITDA does not include the effects of changes in working capital.
Halozyme Therapeutics |
| = | 451.95 M |
In a nutshell, EBITDA is calculated by adding back each of the excluded items to the post-tax profit, and can be used to compare companies with very different capital structures.
Halozyme EBITDA Comparison
Halozyme Therapeutics is currently under evaluation in ebitda category among its peers.
Halozyme Therapeutics Profitability Projections
The most important aspect of a successful company is its ability to generate a profit. For investors in Halozyme Therapeutics, profitability is also one of the essential criteria for including it into their portfolios because, without profit, Halozyme Therapeutics will eventually generate negative long term returns. The profitability progress is the general direction of Halozyme Therapeutics' change in net profit over the period of time. It can combine multiple indicators of Halozyme Therapeutics, where stable trends show no significant progress. An accelerating trend is seen as positive, while a decreasing one is unfavorable. A rising trend means that profits are rising, and operational efficiency may be rising as well. A decreasing trend is a sign of poor performance and may indicate upcoming losses.
| Last Reported | Projected for Next Year | ||
| Accumulated Other Comprehensive Income | -9.3 M | -8.8 M | |
| Operating Income | 337.6 M | 354.5 M | |
| Income Before Tax | 348.3 M | 365.7 M | |
| Total Other Income Expense Net | 10.8 M | 11.3 M | |
| Net Income | 281.6 M | 295.7 M | |
| Income Tax Expense | 66.7 M | 70.1 M | |
| Net Income From Continuing Ops | 281.6 M | 295.7 M | |
| Non Operating Income Net Other | -1.5 M | -1.4 M | |
| Net Income Applicable To Common Shares | 232.4 M | 244.1 M | |
| Interest Income | 4.2 M | 4 M | |
| Net Interest Income | -18.8 M | -19.7 M | |
| Change To Netincome | 60.3 M | 63.3 M | |
| Net Income Per Share | 2.13 | 2.24 | |
| Income Quality | 1.38 | 1.45 | |
| Net Income Per E B T | 0.81 | 0.75 |
Halozyme Profitability Driver Comparison
Profitability drivers are factors that can directly affect your investment outlook on Halozyme Therapeutics. Investors often realize that things won't turn out the way they predict. There are maybe way too many unforeseen events and contingencies during the holding period of Halozyme Therapeutics position where the market behavior may be hard to predict, tax policy changes, gold or oil price hikes, calamities change, and many others. The question is, are you prepared for these unexpected events? Although some of these situations are obviously beyond your control, you can still follow the important profit indicators to know where you should focus on when things like this occur. Below are some of the Halozyme Therapeutics' important profitability drivers and their relationship over time.
Use Halozyme Therapeutics in pair-trading
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Halozyme Therapeutics position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Halozyme Therapeutics will appreciate offsetting losses from the drop in the long position's value.Halozyme Therapeutics Pair Trading
Halozyme Therapeutics Pair Trading Analysis
The ability to find closely correlated positions to Halozyme Therapeutics could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Halozyme Therapeutics when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Halozyme Therapeutics - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Halozyme Therapeutics to buy it.
The correlation of Halozyme Therapeutics is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Halozyme Therapeutics moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Halozyme Therapeutics moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Halozyme Therapeutics can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Use Investing Themes to Complement your Halozyme Therapeutics position
In addition to having Halozyme Therapeutics in your portfolios, you can quickly add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your investment opportunity, you can then find an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility.Did You Try This Idea?
Run Hybrid Mix Funds Thematic Idea Now
Hybrid Mix Funds
Funds or Etfs that are made of portfolios of stocks, bonds, or cash instruments with different maturity horizons and characteristics. The Hybrid Mix Funds theme has 37 constituents at this time.
You can either use a buy-and-hold strategy to lock in the entire theme or actively trade it to take advantage of the short-term price volatility of individual constituents. Macroaxis can help you discover thousands of investment opportunities in different asset classes. In addition, you can partner with us for reliable portfolio optimization as you plan to utilize Hybrid Mix Funds Theme or any other thematic opportunities.
| View All Next | Launch |
Check out Risk vs Return Analysis. To learn how to invest in Halozyme Stock, please use our How to Invest in Halozyme Therapeutics guide.You can also try the Sign In To Macroaxis module to sign in to explore Macroaxis' wealth optimization platform and fintech modules.
To fully project Halozyme Therapeutics' future profitability, investors should examine all historical financial statements. These statements provide investors with a comprehensive snapshot of the financial position of Halozyme Therapeutics at a specified time, usually calculated after every quarter, six months, or one year. Three primary documents fall into the category of financial statements. These documents include Halozyme Therapeutics' income statement, its balance sheet, and the statement of cash flows.